Table 2.
Patient no | Gender | Age | ECOG PS | Histological type | Stage | Primary site | Metastatic site | Prior therapy | Best response | PFS (months) |
---|---|---|---|---|---|---|---|---|---|---|
1 | Male | 50 | 0 | UPS | IV | Upper limb | Lung | Surgery, radiotherapy | PR | 21 |
2 | Male | 55 | 0 | UPS | IV | Lower limb | Lung | Surgery, radiotherapy | SD | 8 |
3 | Male | 63 | 0 | UPS | IV | Thoracic wall | Lung | Surgery | PR | 15 |
4 | Female | 45 | 1 | UPS | IV | Lower limb | Lung | Surgery | SD | 12 |
5 | Male | 56 | 1 | UPS | IV | Lower limb | Lung | Surgery, radiotherapy | CR | 21 |
6 | Female | 52 | 0 | UPS | IV | Lower limb | Lung | Surgery | SD | 4 |
7 | Male | 58 | 0 | UPS | IV | Paravertebral | Lung | Surgery, radiotherapy | PR | 16 |
8 | Male | 62 | 0 | UPS | IV | Upper limb | Lung | Surgery, radiotherapy | PD | 2 |
9 | Male | 53 | 1 | UPS | IV | Upper limb | Lung | Surgery | PR | 18 |
10 | Male | 40 | 0 | Dedifferentiated liposarcoma | IV | Lower limb | Lung | Surgery, radiotherapy | PR | 10 |
11 | Female | 54 | 0 | Dedifferentiated liposarcoma | IIIB | Upper limb | Lymph | Surgery, radiotherapy | PD | 2 |
12 | Male | 63 | 0 | Dedifferentiated liposarcoma | IV | Lower limb | Lung | Surgery | SD | 3 |
13 | Male | 54 | 1 | Dedifferentiated liposarcoma | IV | Lower limb | Lung | Surgery | PD | 2 |
14 | Male | 61 | 0 | Dedifferentiated liposarcoma | IV | Lower limb | Lung | Surgery | SD | 4 |
15 | Male | 52 | 1 | Dedifferentiated liposarcoma | IV | Pelvic girdle | Lung | Surgery | SD | 10 |
16 | Female | 65 | 1 | Angiosarcoma | IV | Thoracic wall | Lung | Surgery | PR | 14 |
17 | Male | 64 | 0 | Angiosarcoma | IIIB | Head and neck | Lymph | Surgery | SD | 7 |
18 | Male | 60 | 0 | Angiosarcoma | IV | Lower limb | Lung | Surgery | PD | 2 |
19 | Female | 48 | 0 | Leiomyosarcoma | IV | Lower limb | Lung | Surgery, radiotherapy | PR | 10 |
20 | Male | 26 | 1 | Leiomyosarcoma | IV | Pelvic girdle | Lung | No | SD | 8 |
21 | Female | 48 | 0 | Leiomyosarcoma | IV | Lower limb | Lung | Surgery | SD | 5 |
22 | Female | 48 | 1 | Synovial sarcoma | IV | Pelvic girdle | Lung | Surgery | PR | 14 |
23 | Female | 40 | 0 | Synovial sarcoma | IV | Pelvic girdle | Lung | Surgery, radiotherapy | PR | 9 |
24 | Female | 26 | 1 | Synovial sarcoma | IIIB | Lower limb | Lymph | No | PR | 10 |
25 | Male | 20 | 1 | Epithelioid sarcoma | IIIB | Lower limb | Lymph | No | PD | 2 |
26 | Male | 32 | 0 | Epithelioid sarcoma | IV | Lower limb | Lung, Lymph | Surgery | PD | 2 |
27 | Female | 36 | 0 | Myxofibrosarcoma | IV | Paravertebral | Lung | Surgery, radiotherapy | SD | 6 |
28 | Female | 42 | 0 | Myxofibrosarcoma | IV | Paravertebral | Lung | No | SD | 8 |
29 | Female | 35 | 0 | Clear cell sarcoma | IV | Lower limb | Lung | No | SD | 7 |
30 | Male | 55 | 0 | Malignant peripheral nerve sheath tumor | IV | Upper limb | Lung, lymph | Surgery | SD | 4 |
CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; UPS, undifferentiated pleomorphic sarcoma.